PMID- 29266325
OWN - NLM
STAT- MEDLINE
DCOM- 20180926
LR  - 20220408
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 72
IP  - 7
DP  - 2018 Jun
TI  - HMGA2, but not HMGA1, is overexpressed in human larynx carcinomas.
PG  - 1102-1114
LID - 10.1111/his.13456 [doi]
AB  - AIMS: Malignant tumours from the upper aerodigestive tract are grouped 
      collectively in the class of head and neck squamous cell carcinoma (HNSCC). The 
      head and neck tumours were responsible for more than 500 000 cancer cases in 
      2012, accounting for the sixth highest incidence rate and mortality worldwide 
      among all tumour types. Laryngeal squamous cell carcinoma (LSCC) possesses the 
      second highest incidence rate among all HNSCC. Despite significant advances in 
      surgery and radiotherapy during the last few decades, no treatment has been shown 
      to achieve a satisfactory therapeutic outcome and the mortality rate of LSCC is 
      still high, with a 5-year survival rate of 64%. Therefore, further investigations 
      are required to identify the pathogenesis of LSCC. METHODS AND RESULTS: In order 
      to search for new LSCC biomarkers, we have analysed the expression of the HMGA 
      family members, HMGA1 and HMGA2, by quantitative reverse transcription-polymerase 
      chain reaction (qRT-PCR) and immunohistochemistry. HMGA proteins are usually 
      absent in the healthy adult tissues. In contrast, their constitutive expression 
      is a feature of several neoplasias, being associated with a highly malignant 
      phenotype and reduced survival. Here, we report HMGA2 overexpression in larynx 
      carcinomas. Conversely, HMGA1 does not show any differences in its expression 
      between normal and carcinoma tissues. Interestingly, HMGA2 overexpression appears 
      associated with that of two HMGA1-pseudogenes, HMGA1P6 and HMGA1P7, acting as a 
      sponge for HMGA1- and HMGA2-targeting microRNAs and involved in several human 
      cancers. CONCLUSIONS: Therefore, HMGA2 overexpression appears to be a strong 
      feature of larynx carcinoma, supporting its detection as a valid tool for the 
      diagnosis of these malignancies.
CI  - (c) 2017 John Wiley & Sons Ltd.
FAU - Palumbo, Antonio Jr
AU  - Palumbo A Jr
AUID- ORCID: 0000-0002-7977-8522
AD  - Programa de Carcinogenese Molecular, Instituto Nacional de Cancer - INCA, Rio de 
      Janeiro, Brazil.
AD  - Laboratorio de Interacoes Celulares, Instituto de Ciencias Biomedicas, 
      Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - De Martino, Marco
AU  - De Martino M
AD  - Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di 
      Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di 
      Napoli, Universita degli Studi di Napoli 'Federico II', Naples, Italy.
FAU - Esposito, Francesco
AU  - Esposito F
AD  - Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di 
      Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di 
      Napoli, Universita degli Studi di Napoli 'Federico II', Naples, Italy.
FAU - Fraggetta, Filippo
AU  - Fraggetta F
AD  - Department of Pathology, Ospedale Cannizzaro, Catania, Italy.
FAU - Neto, Pedro N
AU  - Neto PN
AD  - Programa de Carcinogenese Molecular, Instituto Nacional de Cancer - INCA, Rio de 
      Janeiro, Brazil.
FAU - Valverde Fernandes, Priscila
AU  - Valverde Fernandes P
AD  - Divisao de Patologia, Instituto Nacional de Cancer - INCA, Rua Cordeiro da Graca, 
      Rio de Janeiro, Brazil.
FAU - Santos, Izabella C
AU  - Santos IC
AD  - Secao de Cirurgia de Cabeca e Pescoco, Instituto Nacional de Cancer - INCA, Praca 
      da Cruz Vermelha, Rio de Janeiro, RJ, Brazil.
FAU - Dias, Fernando L
AU  - Dias FL
AD  - Secao de Cirurgia de Cabeca e Pescoco, Instituto Nacional de Cancer - INCA, Praca 
      da Cruz Vermelha, Rio de Janeiro, RJ, Brazil.
FAU - Nasciutti, Luiz E
AU  - Nasciutti LE
AD  - Laboratorio de Interacoes Celulares, Instituto de Ciencias Biomedicas, 
      Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Meireles Da Costa, Nathalia
AU  - Meireles Da Costa N
AD  - Programa de Carcinogenese Molecular, Instituto Nacional de Cancer - INCA, Rio de 
      Janeiro, Brazil.
FAU - Fusco, Alfredo
AU  - Fusco A
AD  - Programa de Carcinogenese Molecular, Instituto Nacional de Cancer - INCA, Rio de 
      Janeiro, Brazil.
AD  - Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di 
      Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di 
      Napoli, Universita degli Studi di Napoli 'Federico II', Naples, Italy.
FAU - Ribeiro Pinto, Luis Felipe
AU  - Ribeiro Pinto LF
AD  - Programa de Carcinogenese Molecular, Instituto Nacional de Cancer - INCA, Rio de 
      Janeiro, Brazil.
LA  - eng
SI  - GENBANK/AB52039
PT  - Journal Article
DEP - 20180309
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HMGA2 Protein)
RN  - 0 (MicroRNAs)
RN  - 124544-67-8 (HMGA1a Protein)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma/*genetics/metabolism/pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - HMGA1a Protein/*genetics/metabolism
MH  - HMGA2 Protein/*genetics/metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/metabolism/pathology
MH  - Larynx/metabolism/pathology
MH  - Male
MH  - MicroRNAs/genetics/metabolism
MH  - Middle Aged
OTO - NOTNLM
OT  - HMGA1
OT  - HMGA2
OT  - HMGA pseudogenes
OT  - carcinoma
OT  - larynx
OT  - microRNA
EDAT- 2017/12/22 06:00
MHDA- 2018/09/27 06:00
CRDT- 2017/12/22 06:00
PHST- 2017/08/29 00:00 [received]
PHST- 2017/12/11 00:00 [accepted]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2018/09/27 06:00 [medline]
PHST- 2017/12/22 06:00 [entrez]
AID - 10.1111/his.13456 [doi]
PST - ppublish
SO  - Histopathology. 2018 Jun;72(7):1102-1114. doi: 10.1111/his.13456. Epub 2018 Mar 
      9.